Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Accumulated Expenses (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Accumulated Expenses for 6 consecutive years, with $3.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 61.1% year-over-year to $3.0 million, compared with a TTM value of $3.0 million through Sep 2025, down 61.1%, and an annual FY2024 reading of $6.0 million, down 8.12% over the prior year.
  • Accumulated Expenses was $3.0 million for Q3 2025 at Ovid Therapeutics, up from $2.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.4 million in Q2 2021 and bottomed at $1.2 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $5.3 million, with a median of $5.4 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses crashed 80.05% in 2021, then surged 190.59% in 2022.
  • Year by year, Accumulated Expenses stood at $7.7 million in 2021, then tumbled by 41.28% to $4.5 million in 2022, then soared by 44.83% to $6.5 million in 2023, then fell by 8.12% to $6.0 million in 2024, then tumbled by 50.63% to $3.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for OVID at $3.0 million in Q3 2025, $2.9 million in Q2 2025, and $6.0 million in Q1 2025.